Fig 3. MNC Biodistribution based on IV and IA Delivery Routes.

Fig 3A: Comparison of IA vs IV delivery of MNC biodistribution at two different doses in brain, lungs, and spleen. At the high dosage of 30 million cells/kg, there were more labeled cells detected in the brain at 1 and 6 hours in the IA group; however, there was no significant difference in labeled cells at later time points. There was no significant difference in labeled cells in the lungs or spleen. At the lower dosage of 1 million cells/kg, there was no difference in labeled cells in any of the organs. Data are Means±SD. *: p< 0.05, compared to IA. N=5 animals per time point each group. Time points reflect time in hours after MNC administration.

Fig 3B: Representative fluorescence images of Q-tracker labeled MNCs in the brain at 24 hours after IA or IV delivery. No labeled MNCs were found in the brains in the sham MCAo model. Red: Q-tracker 655. Blue: DAPI. Co-labeled MNCs (arrow). Maginification: 200X

Fig 3C: Comparison of IA vs IV delivery of high dosage MNCs biodistribution in the peripheral venous circulation. Fig 3C shows flow cytometric analysis and a bar graph representing the percentage of labeled MNCs in the sampled blood. There are no significant differences in labeled MNCs between IV and IA routes in either jugular or femoral vein at 5 minutes and 1 hour after cell infusion, respectively. Compared to 5 minutes after cell infusion, there were significantly less labeled MNCs in the venous circulation at 1 hour after cell infusion (N=4 animals, p<0.05). Data are Means±SD. *: p<0.05, compared to 5 minutes group.

Fig 3D: High dosage MNCs infusion via IA did not cause microinfarcts. Representative fluorescence images of Fluro-J B staining show dead neurons in the infarct area after MCAo. No stained neurons were detected in the sham animals given 3×10⁷ MNCs /kg IA.